Sign Out
Augmentin: Amoxicillin-clavulanate should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. Adult formulations: Co-amoxiclav is indicated for short term treatment of bacterial infections at the following sites when caused by amoxicillin-clavulanate-susceptible organisms: Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media, typically caused by Streptococcus pneumoniae, Haemophilus influenzae#, Moraxella catarrhalis# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia, typically caused by Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.
Genitourinary tract infections e.g. cystitis, urethritis, pyelonephritis and female genital infections typically caused by Enterobacteriaceae# (mainly Escherichia coli#), Staphylococcus saprophyticus and Enterococcus species and gonorrhea caused by Neisseria gonnorhoeae#.
Skin and soft tissue infections typically caused by Staphylococcus aureus#, Streptococcus pyogenes and Bacteroides species#.
Bone and joint infections e.g. osteomyelitis typically caused by Staphylococcus aureus#, where more prolonged therapy may be appropriate.
Dental infections e.g. dentoalveolar abscess
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Pediatric formulations: Co-amoxiclav is indicated for short term treatment of bacterial infections at the following sites when caused by amoxicillin-clavulanate sensitive organisms: Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media typically caused by Streptococcus pneumoniae, Haemophilus influenzae#, Moraxella catarrhalis# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.
Genitourinary tract infections e.g. cystitis, urethritis, pyelonephritis, female genital infections typically caused by Enterobacteriaceae# (mainly Escherichia coli#), Staphylococcus saprophyticus and Enterococcus species and gonorrhea caused by Neisseria gonorrhoeae#.
Skin and soft tissue infections typically caused by Staphylococcus aureus#, Streptococcus pyogenes and Bacteroides species#.
Amoxicillin-clavulanate Paediatric three times daily: The paediatric three times daily dosing regimen is also indicated for the following infections: Bone and joint infections e.g. osteomyelitis typically caused by Staphylococcus aureus#, where more prolonged therapy may be appropriate.
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
All formulations: #Some members of these species of bacteria produce beta-lactamase, rendering them insensitive to amoxicillin alone (see Pharmacology: Pharmacodynamics: Pharmacodynamic effects under Actions for further information).
Susceptibility to amoxicillin-clavulanate will vary with geography and time. Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. Infection caused by amoxicillin-susceptible organisms are amenable to co-amoxiclav treatment due to its amoxicillin content. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with amoxicillin-clavulanate-susceptible beta-lactamase-producing organisms may therefore be treated by co-amoxiclav.
Augmentin ES: Co-amoxiclav (Augmentin) should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Co-amoxiclav (Augmentin ES) is indicated for the short-term treatment of bacterial infections in paediatric patients at the following sites when caused by Co-amoxiclav (Augmentin)-susceptible organisms: Upper respiratory tract infections (including ENT) e.g. recurrent or persistent acute otitis media due to Streptococcus pneumoniae (penicillin minimum inhibitory concentration (MIC) less than or equal to 4 μg/mL), Haemophilus influenzae# and Moraxella catarrhalis#. Such patients are often characterised by antibiotic exposure for acute otitis media within the preceding 3 months, and are either aged ≤2 years or attend daycare; tonsillo-pharyngitis and sinusitis, typically caused by Streptococcus pneumoniae, Haemophilus influenzae#, Moraxella catarrhalis# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.
Skin and soft tissue infections typically caused by Staphylococcus aureus# and Streptococcus pyogenes.
Other Co-amoxiclav (Augmentin) formulations are indicated for short-term treatment of bacterial infections at the following sites when caused by Co-amoxiclav (Augmentin)-susceptible organisms: Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media typically caused by Streptococcus pneumoniae, Haemophilus influenzae#, Moraxella catarrhalis# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis, female genital infections typically caused by Enterobacteriaceae# (mainly Escherichia coli#) Staphylococcus saprophyticus and Enterococcus species, and gonorrhoea caused by Neisseria gonorrhoeae#.
Skin and soft tissue infections typically caused by Staphylococcus aureus#, Streptococcus pyogenes and Bacteroides species#.
#Some members of these species of bacteria produce beta-lactamase, rendering them insensitive to amoxicillin alone (see Pharmacologic Properties: Pharmacodynamics: Pharmacodynamic effects under Actions for further information).
Susceptibility to Co-amoxiclav (Augmentin) will vary with geography and time. Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
